• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Obstetrics and Gynecology Classics

Most ovarian cysts resolve, sonographic surveillance recommended [Classics Series]

byLeah Hawkins Bressler, MD, MPH
November 14, 2015
in Obstetrics and Gynecology Classics, The Classics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The majority (>60%) of ovarian abnormalities, even complex, solid or bilateral cysts, resolved with serial ultrasounds.

2. Complex-appearing cysts resolved more quickly than simple-appearing cysts (8.7 weeks vs. 53.0 weeks, to resolution, respectively, p<0.01).

3. The positive predictive value associated with serial ultrasounds is 24.7% compared to 8.1% with a single ultrasound.

Original date of publication: August 2013

Study Rundown: Ovarian cancer is a rare but deadly diagnosis that carries an overall 5-year survival of 44%. Additionally, classic ovarian cancer symptoms are vague and include pelvic pain, abdominal pain and bloating. To improve detection, various screening methods have been investigated. Carcinoma antigen 125 (CA-125) is a marker of epithelial growth in mullerian (fallopian, endometrial, endocervical) and coelemic (pericardial, pleural and peritoneal) cell lines. Assessment of serum CA-125 levels was evaluated as a marker for ovarian cancer but was found to lack specificity for screening. Transvaginal ultrasonography has been purported to have decent sensitivity (80-100%) and specificity (94-99%) to detect ovarian cancer. However, research from the National Ovarian Cancer Early Detection Program, which screened 4526 women at high risk for ovarian cancer, demonstrated a low predictive ability such that all the cancers diagnosed with ultrasound in their study were Stage III (see relevant reading). Yet, many providers still closely rely on ultrasound to guide management of adnexal masses and specifically use sonographic markers to guide their decision to surgically remove the mass. However, as of early 2013, no literature existed on the disposition of ovarian abnormalities detected by ultrasound, such that information such as how long it takes cysts to resolve and whether time-to-resolution varies with cyst characteristics was unknown. In the present study, researchers performed serial ultrasounds to assess the incidence and disposition of ovarian abnormalities and discovered that most ovarian cysts resolve. Additionally, they found that most complex-appearing cysts resolved more quickly than simple cysts. This landmark study demonstrated that change in cyst characteristics over time is a valuable clinical variable. Their findings discourage surgical intervention on the basis of a single ultrasound and encourage sonographic surveillance of ovarian abnormalities with serial ultrasounds (every 6 months for simple cysts and every 6 weeks-every 3 months for complex cysts) either to resolution or, in the instance of increasing cyst size or complexity, surgical removal.

Strengths include large population-based study sample, 25-year study period and individual review of all abnormalities by the principal investigator. Findings were limited by single-institution study in one state such that findings may not apply to populations with other ethnic compositions. Additionally, the screening algorithm was adjusted over the 25-year study period such that screening intervals varied according to current practice recommendations. This population was at elevated risk for ovarian cancer either due to age or family history and thus results may not apply to a low-risk population.

Click here to read study in Obstetrics & Gynecology

EvidencePulse™by 2 Minute Medicine®

How does Most ovarian cysts resolve, sonographic surveillance recommended apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

Relevant reading: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.

In-Depth [longitudinal prospective cohort study]:  A total of 39 337 women in the University of Kentucky Ovarian Cancer Screening Program were monitored with 221 576 baseline and interval ultrasounds over 25 years. Asymptomatic women >50 years old or women >25 years old with a family history of ovarian cancer were eligible. Ovarian abnormality was defined as ovarian size >2 standard deviations above normal and the presence of cysts (with deputations, ovulations, solid areas or papillary projections) and/or acrogenic solid structures. When abnormal results were identified, repeat ultrasounds were performed from 6 weeks to 6 months later. For women without abnormalities, serial ultrasounds were performed annually. Time-to-resolution, cyst characteristics and surgical pathology were assessed.

Compared to postmenopausal women, the prevalence of sonographic ovarian abnormalities was higher among premenopausal women (34.9% vs. 17.0%, respectively, p<0.001), as was the prevalence of ovarian cysts (15.3% vs. 8.2% p<0.001). Of women with ovarian abnormalities, 63.2% resolved on subsequent ultrasounds. Complex-appearing cysts resolved more quickly than simple-appearing cysts (median resolution time 8.7 vs. 53.0 weeks, respectively, p<0.01). Over the duration of the study, the positive predictive value of sonographic screening increased from 8.1% at the time of initial ultrasound to 24.7% with serial ultrasounds.

More from this author: HPV triage is optimal management for ASCUS [Classics Series], Risks of trial of labor after cesarean delivery (TOLAC) [Classics Series], Vaginal progesterone for sonographic short cervix decreased preterm birth [Classics Series]

Trials since this one

What later trials found on the same question.

  1. 2014

    Letrozole superior to clomid for ovulation induction in PCOS In The Classics

    Women with polycystic ovary syndrome (PCOS) randomized to receive letrozole had more live births than women randomized to clomiphene (27.5% vs. 19.1%, p=0.007).

© 2014 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD

Tags: ovarian cysts

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Obstetrics and gynecology Classics

Previous Post

Oral antibiotics may be noninferior to intravenous in pediatric acute osteomyelitis

Next Post

Imaging of atherosclerotic inflammation possible with fluorine MRI

Next Post

Imaging of atherosclerotic inflammation possible with fluorine MRI

Pre-operative transcranial magnetic stimulation useful for language mapping

Nanoparticle delivery of proteasomes may improve Alzheimer’s therapy [Pre Clinical]

[UKGTS trial] Latanoprost helps preserve visual field in open-angle glaucoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In At-Risk Patients With Moderate Aortic Stenosis, TAVR Reduced 2-Year Death or Heart-Failure Events
  • Nipocalimab patient interviews identify mouth dryness as the most important symptom to improve in phase 2 Sjögren’s disease data
  • CDC reports 5,182 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.